Low-Density Lipoprotein Cholesterol, Non–High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease

American Journal of Cardiology

Volumn 118, Issue 6, 2016, Pages 804-810

  van den Berg, M Johanneke ^a   Visseren, Frank L J ^a,b   de Borst, Gert Jan ^a,b   Kappelle, L Jaap ^a,b   Nathoe, Hendrik M ^a,b   van der Graaf, Yolanda ^a,b   van Petersen, R ^b   van Dinther, B G F ^b   Algra, A ^b   Grobbee, D E ^b   Rutten, G E H M ^b   Leiner, T ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; APOB PROTEIN, HUMAN; APOLIPOPROTEIN B100;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CORONARY ARTERY DISEASE; MORTALITY; MYOCARDIAL INFARCTION; NETHERLANDS; PERIPHERAL ARTERIAL DISEASE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STROKE;

AGED; APOLIPOPROTEIN B-100; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; NETHERLANDS; PERIPHERAL ARTERIAL DISEASE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; STROKE; TRIGLYCERIDES;

EID: 84979739719     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2016.06.048     Document Type: Article

References (20)

1. 1 Arsenault, B.J., Rana, J.S., Stroes, E.S., Despres, J.P., Shah, P.K., Kastelein, J.J., Wareham, N.J., Boekholdt, S.M., Khaw, K.T., Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol 55 (2009), 35–41.
2. 2 Di Angelantonio, E., Sarwar, N., Perry, P., Kaptoge, S., Ray, K.K., Thompson, A., Wood, A.M., Lewington, S., Sattar, N., Packard, C.J., Collins, R., Thompson, S.G., Danesh, J., Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302 (2009), 1993–2000.
3. 3 Ingelsson, E., Schaefer, E.J., Contois, J.H., McNamara, J.R., Sullivan, L., Keyes, M.J., Pencina, M.J., Schoonmaker, C., Wilson, P.W., D'Agostino, R.B., Vasan, R.S., Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 298 (2007), 776–785.
4. 4 Pischon, T., Girman, C.J., Sacks, F.M., Rifai, N., Stampfer, M.J., Rimm, E.B., Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112 (2005), 3375–3383.
5. 5 Sondermeijer, B.M., Rana, J.S., Arsenault, B.J., Shah, P.K., Kastelein, J.J., Wareham, N.J., Boekholdt, S.M., Khaw, K.T., Non-HDL cholesterol vs. apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study. Eur J Clin Invest 43 (2013), 1009–1015.
6. 6 Nordestgaard, B.G., Varbo, A., Triglycerides and cardiovascular disease. Lancet 384 (2014), 626–635.
7. 7 Arsenault, B.J., Boekholdt, S.M., Kastelein, J.J., Lipid parameters for measuring risk of cardiovascular disease. Nat Rev Cardiol 8 (2011), 197–206.
8. 8 Barter, P.J., Ballantyne, C.M., Carmena, R., Castro Cabezas, M., Chapman, M.J., Couture, P., de Graaf, J., Durrington, P.N., Faergeman, O., Frohlich, J., Furberg, C.D., Gagne, C., Haffner, S.M., Humphries, S.E., Jungner, I., Krauss, R.M., Kwiterovich, P., Marcovina, S., Packard, C.J., Pearson, T.A., Reddy, K.S., Rosenson, R., Sarrafzadegan, N., Sniderman, A.D., Stalenhoef, A.F., Stein, E., Talmud, P.J., Tonkin, A.M., Walldius, G., Williams, K.M., Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 259 (2006), 247–258.
9. 9 Mahajan, N., Ference, B.A., Arora, N., Madhavan, R., Bhattacharya, P., Sudhakar, R., Sagar, A., Wang, Y., Sacks, F., Afonso, L., Role of non-high-density lipoprotein cholesterol in predicting cerebrovascular events in patients following myocardial infarction. Am J Cardiol 109 (2012), 1694–1699.
10. 10 Boekholdt, S.M., Arsenault, B.J., Mora, S., Pedersen, T.R., LaRosa, J.C., Nestel, P.J., Simes, R.J., Durrington, P., Hitman, G.A., Welch, K.M., DeMicco, D.A., Zwinderman, A.H., Clearfield, M.B., Downs, J.R., Tonkin, A.M., Colhoun, H.M., Gotto, A.M. Jr., Ridker, P.M., Kastelein, J.J., Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 307 (2012), 1302–1309.
11. 11 Achterberg, S., Cramer, M.J., Kappelle, L.J., de Borst, G.J., Visseren, F.L., van der Graaf, Y., Algra, A., Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: the SMART study. Eur J Cardiovasc Prev Rehabil 17 (2010), 424–430.
12. 12 Simons, P.C., Algra, A., van de Laak, M.F., Grobbee, D.E., van der Graaf, Y., Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol 15 (1999), 773–781.
13. 13 Friedewald, W.T., Levy, R.I., Fredrickson, D.S., Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972), 499–502.
14. 14 Tremblay, A.J., Morrissette, H., Gagne, J.M., Bergeron, J., Gagne, C., Couture, P., Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with beta-quantification in a large population. Clin Biochem 37 (2004), 785–790.
15. 15 Holewijn, S., den Heijer, M., Swinkels, D.W., Stalenhoef, A.F., de Graaf, J., Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk. J Intern Med 268 (2010), 567–577.
16. 16 Lau, J.F., Smith, D.A., Advanced lipoprotein testing: recommendations based on current evidence. Endocrinol Metab Clin North Am 38 (2009), 1–31.
17. 17 Sattar, N., Williams, K., Sniderman, A.D., D'Agostino, R. Jr., Haffner, S.M., Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation 110 (2004), 2687–2693.
18. 18 Stam-Slob, M.C., van der Graaf, Y., de Borst, G.J., Cramer, M.J., Kappelle, L.J., Westerink, J., Visseren, F.L., Effect of type 2 diabetes on recurrent major cardiovascular events for patients with symptomatic vascular disease at different locations. Diabetes Care 38 (2015), 1528–1535.
19. 19 Sniderman, A., Williams, K., Cobbaert, C., ApoB versus non-HDL-C: what to do when they disagree. Curr Atheroscler Rep 11 (2009), 358–363.
20. 20 Colantonio, L.D., Bittner, V., Reynolds, K., Levitan, E.B., Rosenson, R.S., Banach, M., Kent, S.T., Derose, S.F., Zhou, H., Safford, M.M., Muntner, P., Association of serum lipids and coronary heart disease in contemporary observational studies. Circulation 133 (2016), 256–264.